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The liver is bestowed with the capacity to regenerate, which
is a unique attribute for an adult organ. This regenerative
capacity is essential perhaps due to its strategic location and
its indispensable functions for host survival, including syn-
thesis, metabolism, and detoxiﬁcation.1 The cellular and
molecular basis of liver regeneration has been studied for
decades using two major types of models. Partial hepatec-
tomy entails surgically removing three of the ﬁve lobes in a
mouse or three of the four lobes in a rat, amounting to
removal of two-thirds of the entire liver mass.2 This sets in
motion a cascade of events that allows for the residual he-
patocytes to undergo cell division and cell hypertrophy to
make up for the lost mass within days. This has been the basis
of successful partial hepatectomies and split liver trans-
plantation3 in patients. Toxicant-induced liver injury also
promotes speciﬁc cell and molecular signaling that allows for
a partially injured liver to recover via hepatocyte prolifera-
tion. A classical example is the use of a sublethal dose of
acetaminophen that results in pericentral necrosis followed
by proliferation of hepatocytes in spared zones to restore
hepatic architecture.4 In addition to these two models, yet
another form of regeneration stems from the proliferation of
resident hepatocytes by direct mitogens in the absence of any
liver injury. These classes of direct mitogens include triio-
dothyronine (T3), peroxisome proliferators, lead nitrate, and
9-cis retinoic acid, among others.5
Careful dissection of pathways using genetic approaches,
inhibitors, and antisense strategies has yielded highly rele-
vant information that demonstrates a certain degree of
redundancy at the cellular and molecular levels that ensure
hepatic health during the hours of insult. Such molecular
redundancy is evident in a number of knockout mouse
models for which absence of a single gene is rather easilyCopyright ª 2014 American Society for Investigative Pathology.
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http://dx.doi.org/10.1016/j.ajpath.2013.11.004compensated by activation of another pathway that then
drives hepatocyte proliferation to restore liver mass in models
such as partial hepatectomy.6 A classic example is the delay
in liver regeneration when hepatocyte-speciﬁc ß-catenine or
Meteknockout mice are subjected to partial hepatectomy.7,8
Cellular redundancy also ensures proper liver regeneration.
Although mature epithelial cells of the liver (ie, hepatocytes
and cholangiocytes) have been convincingly shown to
replicate and restore the lost hepatic mass, these cells can also
transdifferentiate into one another to repair the lost cell type.6
This is primarily driven by cell-selective injury that may
induce a cell to crossover to the other cell type, which is
developmentally reasonable because there is a common
progenitor precursor of these two epithelial cell types. Yet
another level of cellular redundancy comes from adult liver
progenitors or oval cells that expand and differentiate into the
cell of choice in response to an overwhelming hepatic insult
or due to the inability of adult cells to divide in response to an
adverse liver environment.9 Among the last-resort cellular
redundancies contributing to restoration of liver structure and
function during duress may be the extrahepatic cell sources
such as bone marrowederived stem cells that contribute to
hepatic repair through mechanisms, which are incompletely
understood.10
With exhaustion or failure of redundant mechanisms to
act such as during an overwhelming acute insult, the liver
decompensates requiring a patient to seek medical attention.
This may also occur when injury to the liver is acute and
Guest Editorialoverwhelming. A signiﬁcant subset of patients with end-
stage liver disease requires liver transplantation as the only
effective treatment.3 This is severely limited, however, by
the dearth of donor organs. Thus, progress toward deﬁning
therapies for end-stage liver disease includes identiﬁcation
of novel strategies that broadly encompass the discipline of
hepatic regenerative medicine. In the current issue of The
American Journal of Pathology, four timely topics relevant
to this area are reviewed in depth.
Hepatic Metabolism and Regeneration
Stimulating liver regeneration by various modalities may be
highly relevant as a therapy for end-stage liver disease and
may have implications for liver transplantation. Although we
understand the process of hepatic regeneration relatively
well, what initiates it has continued to evade us. Since liver
performs key metabolic, synthetic, and detoxiﬁcation func-
tions, recent studies have started to investigate if sensing of a
temporal deﬁcit in any of these constitutive hepatic functions
after procedures like hepatectomy may in fact be the initiator
signal for the regeneration process. Several reports have now
shown changes in fat and glucose metabolism in the liver
during the early hours after partial hepatectomy. In fact,
modulation of these metabolic alterations after partial hepa-
tectomy has led to an impairment of the regenerative pro-
cess.11 Lessons learned from these studies will have
signiﬁcant bearing on how to best induce regeneration in a
setting of chronic or acute liver insufﬁciency by altering the
metabolic load, and this may have both biological and clin-
ical implications. Huang and Rudnick12 overview the data
supporting a metabolic model of liver regeneration and
reﬂect on clinical implications and areas for further study.
Polyploidy and Liver
Another hallmark of a normal adult liver is the existence of
polyploidy. In fact, more than half of the hepatocytes in adult
human liver and up to 90% of hepatocytes in rodent liver
display polyploidy. Most of the polyploidy in hepatocytes
has been shown to be a function of failed cytokinesis.
Intriguingly, a major pathway implicated in this process is
insulin-Akt signaling.13 Although liver is normally com-
posed of polyploid hepatocytes, speciﬁc situations can lead to
additional changes in ploidy, including iron overload, altered
redox state of a cell, and partial hepatectomy.14 The existence
of polyploidy in the liver has been known for more than a
century, but the features unique to polyploid hepatocytes and
their function are a timely concept. Two major theoretical
advantages of polyploid hepatocytes include a functional
hepatocyte and a more robust or resistant cell to genotoxic or
environmental stress. Both of these related functions repre-
sent a gene-dosage effect due to higher copies of speciﬁc
synthetic or metabolic genes present in a cell with higher
ploidy. Thus, understanding the regulation of ploidy can haveThe American Journal of Pathology - ajp.amjpathol.orgfar-reaching consequences in hepatic regenerative medicine,
speciﬁcally in repair and restoration of hepatic function after
surgical or toxicant-induced liver injury, as well as in tissue
engineering and cell therapy. Gentric and Desdouets15
explore the mechanisms that lead to the development of
polyploid cells, our current state of understanding of how
polyploidization is regulated during liver growth, and its
consequence on liver function.
Human iPS Cell-Derived Hepatocytes
With the advent of technologies enabling reprogramming of
adult somatic cells to a pluripotent state, the ﬁeld has gained
much momentum.16 For the ﬁrst time, it is now theoretically
possible to model a disease from every patient through gen-
eration of induced pluripotent stem (iPS) cells and inducing
their differentiation to the affected tissue. This is particularly
interesting with monogenetic diseases that remain poorly
characterized from a biological standpoint. However, these
iPS cells also represent an innovative cell source for regener-
ative medicine, as these cells can differentiate into any mature
cell such as a hepatocyte for applications in cell therapy, tissue
engineering, and bioartiﬁcial liver devices.17 Although this is
an attractive concept due to a host immunological tolerance,
the ﬁeld still faces challenges such as limited efﬁciency to
induce pluripotency, lack of an ideal cell source for generating
an iPS cell due to its retainedmemory, and inability to generate
fully functional mature hepatocytes from iPS cells. Several
relevant studies are now examining normal prenatal devel-
opment of the liver to identify key cellular and molecular in-
teractions that in turn can be temporally applied to iPS cells in
culture. This strategy is an effort to mimic ontogeny and
effectively generate fully differentiated functional hepatocytes
from these stem cells. This highly innovative advance may
have a major impact on the way we study and treat speciﬁc
diseases of the liver and other organs. Si-Tayeb and col-
leagues18 reviewed the choice of somatic cells to be reprog-
rammed by emergent new and nonintegrative strategies,
as well as the application of differentiated human-induced
pluripotent stem cells in hepatology.
Decellularized Hepatic Matrix and Hepatic
Tissue Engineering
Due to the shortage of organs for transplant, research on
alternate modalities, such as hepatic tissue engineering has
gained momentum. Additionally, there is a need to engineer
whole organs in a three-dimensional conﬁguration to better
understand cellecell interactions from a biological and func-
tional perspective. The applications of such engineered organs
could be envisioned not just in the setting of transplantation,
but also in areas such as toxicology, disease modeling, and
drug development. However, there have beenmajor hurdles to
engineering the liver, such as lack of optimal cell source,
maintenance of function, and longevity of these engineered307
Mongatissues. With the advent of iPS cells, an autologous cell source
may no longer be an issue, although its differentiation to
mature hepatocyte still remains a challenge. An innovative
advance in the arena to further the maturation of a hepatocyte
from iPS cells has been the realization of an important role of
extracellular matrix in maintenance of differentiated hepato-
cyte phenotype. Rather than using combinations of various
matrices to facilitate hepatocyte differentiation, a unique
strategy recently used was to derive intact extracellular matrix
from a liver using a decellularization process. Using the whole
organ acellular matrix as a three-dimensional scaffold for
seeding hepatocyte-like cells derived from iPS cells, a fully
functional hepatocyte may become a reality. In addition,
use of nonparenchymal cells of the liver in such a tissue-
engineering strategy may provide an intricate spatiotemporal
environment that may be ideal for generating a functional and
optimal organ for any number of applications.19,20 This is
truly an evolving and timely ﬁeld with much ongoing research
focused at optimizing engineering of an organ for ex-
perimental and translational purposes. Soto-Gutierrez and
colleagues21 highlight the most recent advances in organ as-
sembly regarding the development of liver tissue in vitro.Concluding Remarks
The liver’s will to live is effectively supported by a host of
cellular and molecular means that provide a tiered restora-
tion mechanism ensuring hepatic homeostasis. We hope that
this series of reviews will help illuminate these pathways for
our readers and provide a clearer picture of the state of the
art of hepatic regenerative medicine.References
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